ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/hepatic/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Hepatic - Advanced/metastatic
19
trial(s) found.
NCT07722741
Curative
Phase 2
Recruiting
IMPACT31
: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
DNA plasmid encoding IL-12
personalized neoantigen vaccine
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07628751
Radonc
NA
Recruiting
A Randomized Controlled Trial of Standard Of Care Versus Radio Ablation in Early Stage Hepatocellular Carcinoma (
SOCRATES-HCC
)
Eicosapentaenoic acid
Radiotherapy
cancer therapy
omega-3 fatty acid
Hepatocellular carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT07623369
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors (
HH160-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology
NCT07369505
Advanced
Phase 1
Recruiting
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane) (
SP-03-B101
)
aromatase inhibitor
mTORC1/mTORC2 inhibitor
Breast cancer
Clear cell renal cell carcinoma
Hepatocellular carcinoma
Neuroendocrine tumour
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07341737
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07291076
Advanced
Phase 1 / Phase 2
Recruiting
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (
CA266-0006
)
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06953089
Advanced
Phase 2
Recruiting
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors (
DB-1311-201
)
anti-B7H3 antibody-drug conjugate
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-Trop2 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Cervical cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
NSW
2060 - North Sydney - Mater Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06921785
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (
ARTEMIDE-HCC01
)
anti-CTLA4 monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/TIGIT antibody
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NA
NA
NCT06910657
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Cancer Research SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06427941
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (
BGB-B2033-101
)
anti-GPC3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Hepatocellular carcinoma
Squamous non-small-cell lung cancer
Yolk sac tumour
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06330064
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
NOT Sarcoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05919264
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors (
FOG-001-101
)
CTNNB1/TCF4 inhibitor
Adamantinomatous craniopharyngioma
Aggressive fibromatosis
Cancer
Castrate-resistant prostate cancer
Colorectal cancer
Endometrial carcinoma
Hepatocellular carcinoma
Microsatellite instability-high colorectal cancer
Microsatellite stable colorectal cancer
Prostate cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05169177
Radonc
Recruiting
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy (
ROCK-RT
)
radiotherapy
Hepatocellular carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
Amezalpat
Atezolizumab
Bevacizumab
HIF2a inhibitor
Imdatifan
Muzastotug
PPAR-alpha inhibitor
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12626000350325
Advanced
Phase 1
Not yet recruiting
Phase I/Ib, Open-label, Dose Escalation and Expansion Study to Assess the safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of ACS2015, Non-viral Gene-modified CAR-T Cells in Patients with Advanced Solid Tumors Expressing EPHB4 (
CARTiEr-E312
)
autologous CAR-T-cell therapy,EPHB4-targeting
Bone cancer
Colorectal cancer
Hepatocellular carcinoma
Soft tissue sarcoma
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12624001345572
Curative
Phase 2
Recruiting
DEFINERx050
: A Multicentre, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab (Anti-VEGF Antibody) as Neo-Adjuvant ImmunoTherapy Versus Active Surveillance in Hepatocellular Carcinoma Patients with high Onco-Fetal Characteristics Before Surgical Resection
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
Hepatocellular carcinoma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (18)
Not yet recruiting (1)
Recruitment Country and State
NSW (11)
QLD (8)
VIC (8)
SA (6)
NZ (3)
WA (1)
Phase
Phase 1 (8)
Phase 1 / Phase 2 (5)
Phase 2 (3)
Phase 3 (1)
Trial Type
Advanced (15)
Curative (2)
Radonc (2)
Cancer Therapy Class
PD-1/PD-L1
42%
VEGF
32%
PD-1
26%
PD-L1
26%
CTLA4
21%
VEGFA
16%
B7H3
16%
oestrogen axis
11%
TIGIT
11%
IL-12
5%
mTOR
5%
mTORC1
5%
mTORC2
5%
Trop2
5%
ER alpha
5%
GPC3
5%
MET
5%
SMO
5%
CTNNB1
5%
HIF2a
5%
IL-6
5%
LAG3
5%
PPAR-alpha
5%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
4215 - Southport - Tasman Oncology (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
2060 - North Sydney - Mater Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
NA
3004 - Melbourne, Southbank - Alfred Health (1)
2109 - North Ryde - Macquarie University Hospital (1)
5000 - Adelaide - Cancer Research SA (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
Cancer Type
Cancer
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Solid tumour
Upper gastrointestinal cancer
Gynaecological cancer
Breast cancer
Urogenital cancer
Colorectal cancer
Lower gastrointestinal cancer
Thoracic cancer
Ovarian cancer
Endometrial cancer
Head and neck cancer
Lung cancer
Respiratory tract cancer
Pancreatic cancer
Pancreatobiliary cancer
Cervical cancer
Gastroesophageal cancer
HPV-related cancer
HPV16-positive cancer
Head and neck squamous cell carcinoma
Kidney cancer
Non-small cell lung cancer
Oesophageal cancer
Viral-related cancer
Male genital cancers
Melanoma
Clear cell renal cell carcinoma
Gastric cancer
Prostate cancer
Sarcoma
Bladder cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Breast adenocarcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Triple-negative breast cancer
Urothelial carcinoma
Skin cancer
Colorectal adenocarcinoma
Castrate-resistant prostate cancer
Epithelial Ovarian Cancer
Prostate adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Neuroendocrine tumour
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
Germ cell tumour
Non-seminoma
Squamous non-small-cell lung cancer
Testicular cancer
Yolk sac tumour
Cutaneous melanoma
Gastrooesophageal adenicarcoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Biliary tract cancer
Oesophageal squamous cell carcinoma
Adamantinomatous craniopharyngioma
Aggressive fibromatosis
Endocrine gland cancer
Endometrial carcinoma
Microsatellite instability-high colorectal cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Pituitary gland cancer
Bone cancer
Soft tissue sarcoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy